Durable responses to Erlotinib despite KRAS mutations in two patients with metastatic lung adenocarcinoma. [electronic resource]
Producer: 20100927Description: 1385-1387 p. digitalISSN:- 1569-8041
- Adenocarcinoma -- drug therapy
- Antineoplastic Agents -- therapeutic use
- Erlotinib Hydrochloride
- Humans
- Lung Neoplasms -- drug therapy
- Mutation -- physiology
- Neoplasm Metastasis
- Proto-Oncogene Proteins -- genetics
- Proto-Oncogene Proteins p21(ras)
- Quinazolines -- therapeutic use
- Remission Induction
- Time Factors
- ras Proteins -- genetics
No physical items for this record
Publication Type: Case Reports; Letter; Research Support, Non-U.S. Gov't; Review
There are no comments on this title.
Log in to your account to post a comment.